Principia Biopharma Inc-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Principia Biopharma Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8013509
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月28日
◆ページ数:22
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Principia Biopharma Inc (Principia Biopharma) is a biopharmaceutical company that designs and develops oral small molecule drug therapies. The company’s proprietary Tailored Covalency technology helps to develop portfolio of drugs such as Bruton’s tyrosine kinase (BTK) inhibitor, Interleukin 17 pathway inhibitor and fibroblast growth factor receptor inhibitor for the treatment of rheumatoid arthritis and other autoimmune and inflammatory diseases. Its drug candidate, PRN1008, a reversible covalent BTK inhibitor, is in Phase 2 development for pemphigus vulgaris, an orphan autoimmune disease and PRN1371 is in Phase 1 for solid tumors. Principia Biopharma is headquartered in San Francisco, California, the US.

Principia Biopharma Inc – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Principia Biopharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Principia Biopharma Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Principia Biopharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Principia Biopharma Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Principia Biopharma Inc, Medical Devices Deals, 2011 to YTD 2017 9
Principia Biopharma Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Principia Biopharma Inc, Pharmaceuticals & Healthcare, Deal Details 11
Venture Financing 11
Principia Biopharma Raises US$50 Million In Series B Venture Financing 11
Principia Biopharma Raises Additional US$13 Million In Series A Financing 13
Principia Biopharma Raises US$12 Million In First Tranche Of Series A Financing 15
Partnerships 16
AbbVie and Principia Biopharma Enter into Agreement 16
Guardant Health Enters into Agreement with Principia Biopharma 17
Licensing Agreements 18
Sanofi to Enter into Licensing Agreement with Principia Biopharma 18
Principia Biopharma Inc – Key Competitors 19
Principia Biopharma Inc – Key Employees 20
Principia Biopharma Inc – Locations And Subsidiaries 21
Head Office 21
Appendix 22
Methodology 22
About GlobalData 22
Contact Us 22
Disclaimer 22

List of Tables
Principia Biopharma Inc, Pharmaceuticals & Healthcare, Key Facts 2
Principia Biopharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Principia Biopharma Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Principia Biopharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Principia Biopharma Inc, Deals By Therapy Area, 2011 to YTD 2017 8
Principia Biopharma Inc, Medical Devices Deals, 2011 to YTD 2017 9
Principia Biopharma Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Principia Biopharma Raises US$50 Million In Series B Venture Financing 11
Principia Biopharma Raises Additional US$13 Million In Series A Financing 13
Principia Biopharma Raises US$12 Million In First Tranche Of Series A Financing 15
AbbVie and Principia Biopharma Enter into Agreement 16
Guardant Health Enters into Agreement with Principia Biopharma 17
Sanofi to Enter into Licensing Agreement with Principia Biopharma 18
Principia Biopharma Inc, Key Competitors 19
Principia Biopharma Inc, Key Employees 20

★海外企業調査レポート[Principia Biopharma Inc-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Qiagen NV (QIA)-医療機器分野:企業M&A・提携分析
    Summary Qiagen NV (Qiagen) is a provider of molecular testing solutions. Its solutions include sample and assay technologies, bioinformatics and automation systems. Qiagen’s sample technologies help isolate and process DNA, RNA and proteins from samples such as blood and tissue. The company’s produc …
  • Societe Des Bains De Mer Sa
    Societe Des Bains De Mer Sa - Strategy, SWOT and Corporate Finance Report Summary Societe Des Bains De Mer Sa - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • Unum Group:戦略・SWOT・企業財務分析
    Unum Group - Strategy, SWOT and Corporate Finance Report Summary Unum Group - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actio …
  • Quorum Health Corp (QHC):企業の財務・戦略的SWOT分析
    Summary Quorum Health Corp (QHC) is a healthcare service provider that offers outpatient services. The center owns and leases hospitals and outpatient centers across the US. Its hospitals provides general hospital health-care services including general acute care, emergency room, general and special …
  • Seiko Epson Corporation:企業の戦略・SWOT・財務分析
    Seiko Epson Corporation - Strategy, SWOT and Corporate Finance Report Summary Seiko Epson Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • China Mengniu Dairy Co Ltd:企業のM&A・事業提携・投資動向
    China Mengniu Dairy Co Ltd - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's China Mengniu Dairy Co Ltd Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acqui …
  • ManpowerGroup Inc (MAN):企業の財務・戦略的SWOT分析
    ManpowerGroup Inc (MAN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • BRT Apartments Corp.:企業の戦略・SWOT・財務情報
    BRT Apartments Corp. - Strategy, SWOT and Corporate Finance Report Summary BRT Apartments Corp. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • ICA Gruppen AB:企業の戦略・SWOT・財務情報
    ICA Gruppen AB - Strategy, SWOT and Corporate Finance Report Summary ICA Gruppen AB - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • Total E&P USA Inc:石油・ガス:M&Aディール及び事業提携情報
    Summary Total E&P USA Inc (TEP USA) formerly Elf Exploration Inc, a subsidiary of Total S.A., is an energy service providing company that explores and produces crude oil and natural gas. The company offers offshore oil production and exploration in the Gulf of Mexico to onshore unconventional shale …
  • Norton Healthcare Inc-製薬・医療分野:企業M&A・提携分析
    Summary Norton Healthcare Inc (Norton Healthcare) is a healthcare service provider that offers medical services. The center offers services such as cancer care, bariatric and weight management, diabetes and endocrine, gastroenterology, clinical trials, pain management, bone marrow transplantation, d …
  • Briscoe Group Limited (BGP):企業の財務・戦略的SWOT分析
    Briscoe Group Limited (BGP) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • Mr. Price Group Ltd.
    Mr. Price Group Ltd. - Strategy, SWOT and Corporate Finance Report Summary Mr. Price Group Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • NATS Holdings Limited:企業の戦略・SWOT・財務情報
    NATS Holdings Limited - Strategy, SWOT and Corporate Finance Report Summary NATS Holdings Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Putnam Investments LLC:企業の戦略的SWOT分析
    Putnam Investments LLC - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • Sasol Ltd (SOL)-エネルギー分野:企業M&A・提携分析
    Summary Sasol Ltd (Sasol) is an integrated energy and chemical company. It develops and commercializes technologies; and builds and operates facilities to produce a range of products, including liquid fuels, chemicals, and low-carbon electricity. The company’s product offerings include olefins and s …
  • Select Energy Services Inc (WTTR):企業の財務・戦略的SWOT分析
    Select Energy Services Inc (WTTR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and we …
  • NOW Health Group Inc:企業の戦略・SWOT・財務情報
    NOW Health Group Inc - Strategy, SWOT and Corporate Finance Report Summary NOW Health Group Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • amcure GmbH:製薬・医療:M&Aディール及び事業提携情報
    Summary Amcure GmbH (Amcure) is a biopharmaceutical company that discovers and develops therapeutics for the treatment of cancer. The company develops peptide-based compounds for the treatment of metastatic forms of cancer. Its lead candidate, AMC303 is used for the treatment of metastatic epithelia …
  • Kodiak Sciences Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Kodiak Sciences Inc (Kodiak Sciences), formerly Oligasis LLC is a drug development company that discovers new medicines for the healthcare sector. The company provides retinal medicines for treatment of wet and dry forms of age-related macular degeneration. It utilizes proprietary Bioconjuga …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆